Imunon Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _______________ Commission file number: 001-15911 Imunon, Inc.(Exact name of Registrant as specified in its charter) Delaware52-1256615(State or other jurisdiction of(I.R.S. Employer incorporation or organization)Identification Number) 997 Lenox Drive, Suite 100,Lawrenceville,NJ 08648(Address of principal executive offices) (609) 896-9100(Registrant’s telephone number, including area code) NA(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act Title of each classTrading symbol(s)Name of each exchange on which registeredCommon stock, par value $0.01 per shareIMNNNasdaq Capital Market Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by checkmark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theRegistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check One): Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 10, 2026, the Registrant had 5,611,403 shares of common stock, $0.01 par value per share, outstanding. IMUNON, INC.QUARTERLY REPORT ONFORM 10-QTABLE OF CONTENTS Page(s)PART I: FINANCIAL INFORMATION4Item 1.Financial Statements4Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 20254Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2026and 20256Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2026 and 20257Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) for the Three Months EndedJune 30, 2026 and 20258Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) for the Six Months Ended June30, 2026 and 20259Notes to the Condensed Consolidated Financial Statements (Unaudited)10Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations22Item 3.Quantitative and Qualitative Disclosures about Market Risk38Item 4.Controls and Procedures38PART II:OTHER INFORMATION39Item 1.Legal Proceedings39Item 1A.Risk Factors39Item 2.Unregistered Sales of Equity Securities and Use of Proceeds39Item 3.Defaults Upon Senior Securities39Item 4.Mine Safety Disclosures39Item 5.Other Information39Item 6.Exhibits39SIGNATURES402 Cautionary Note Regarding Forward-Looking Statements This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements otherthan statements of historical fact are “forward-looking statements” for purposes of this Quarterly Report on Form 10-Q, including,without limitation, any projections of earnings, revenue or other financial items, any statements of the plans and objectives ofmanagement for future operations (including, but not limited to, pre-clinical development, clinical trials, manufacturing andcommercialization), uncertainties and assumptions regarding any continuing impact of the COVID-19 pandemic on our business,operations, clinical trials, supply chain, strategy, goals and anticipated timelines, any statements concerning proposed drug candidates,potential therapeutic benefits, or other new products or services, any statements regarding future economic conditions or performance,any changes in the course of research and development ac